MYRBETRIQ
Peakmirabegron
Mechanism of Action
Adrenergic beta3-Agonists
beta3-Adrenergic Agonist
Clinical Trials (5)
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants
Loss of Exclusivity
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8772315 | Oct 30, 2028 | U-2300 | |
| 8772315*PED | Apr 30, 2029 | — | |
| 12059409 | Sep 28, 2029 | Product | — |
| 10842780 | Sep 28, 2029 | Product | U-2996 |
| 11707451 | Sep 28, 2029 | U-3670 |